Statistically significant (p<0.0001) and clinically meaningful improvement in Hamilton Anxiety Rating Scale (“HAM-A”) of ~10 ...

Discusses Phase II Results for HLP004 in Generalized Anxiety Disorder March 5, 2026 7:30 AM ESTCompany ParticipantsMichael Cola - ...

Helus Pharma (HELP) stock falls as the company posts mid-stage trial data for HLP004, a psychedelic-based therapy for generalized anxiety disorder. Read more here.

Please provide your email address to receive an email when new articles are posted on . Treatment of generalized anxiety disorder with an antidepressant increased the treatment response rate by 41%.

Generalized anxiety disorder affects 1 in 20 U.S. adults. Those with serious symptoms may isolate themselves to the point they rarely leave their home and are unable to work and build meaningful ...

News Commentary - Treatments for Generalized Anxiety Disorder (GAD) are getting better and more accessible, which is good news ...

Individuals with generalized anxiety disorder (GAD), a condition characterized by daily excessive worry lasting at least six months, have a high relapse rate even after receiving treatment. Artificial ...

The latest announcement is out from Cybin ( (HELP) ).

Cognitive behavioral therapy (CBT) should be considered first-line treatment for generalized anxiety disorder in adults, according to a systematic review and network meta-analysis of 66 randomized ...

CLEVELAND — Researchers narrowed down what appears to be the correct dosage during a first ever rigorous clinical trial examining LSD as a treatment for generalized anxiety disorder, with results ...

The U.S. Food and Drug Administration last week granted “breakthrough therapy” status to a form of the psychedelic drug LSD as a treatment for anxiety. The drug, a form of LSD (lysergide d-tartrate) ...

Helus Pharma HELP shares are down on Thursday following the announcement of topline results from a Phase 2 signal detection study for HLP004, a potential treatment for generalized anxiety disorder ...